Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands |
12 Months Ended | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
||||||||||
Profit or loss [abstract] | ||||||||||||
General and administrative expenses | $ 12,729 | $ 16,567 | $ 2,723 | |||||||||
Research and development expenses | 3,059 | 2,711 | 1,898 | |||||||||
Selling and marketing expenses | 992 | 661 | 569 | |||||||||
Impairment and amortization | 11,085 | |||||||||||
Listing expenses | 16,802 | |||||||||||
Operating loss | (27,865) | (36,741) | (5,190) | |||||||||
Finance expenses | 13,493 | 7,891 | 1,128 | |||||||||
Finance income | 5,957 | 1,580 | 28 | |||||||||
Gain from remeasurement of investment in associated company | 22,164 | |||||||||||
Share of net profit (loss) of associated companies | (101) | 106 | ||||||||||
Loss before income tax | (35,401) | (20,989) | (6,184) | |||||||||
Income tax | ||||||||||||
Net loss | (35,401) | (20,989) | (6,184) | |||||||||
Other comprehensive loss: | (1,265) | (283) | (760) | |||||||||
Total comprehensive loss | (36,666) | (21,272) | (6,944) | |||||||||
Net loss attributable to: | ||||||||||||
Equity holders of the Company | (31,092) | (20,914) | ||||||||||
Non- controlling interest | $ (4,309) | $ (75) | ||||||||||
Basic loss per share attributable to shareholders | [1] | $ (1,017) | $ (68,079) | $ (73,599) | [2] | |||||||
Diluted loss per share attributable to shareholders | [1],[3] | $ (1,017) | $ (68,079) | $ (73,599) | [2],[4] | |||||||
|